Results 111 to 120 of about 29,860 (191)

The safety and efficacy of different anti-tuberculosis regimens containing Lzd for RR/MDR/Pre-XDR-TB patients in China. [PDF]

Medicine (Baltimore)
Tang XZ, Ma Y, Tang SJ, Chen Q, Zou LP, Fu XY, Huang T, Wu GH.   +7 more
europepmc   +1 more source

A Case of Transmission of Bedaquiline- and Linezolid-Resistant Tuberculosis. [PDF]

Int J Mol Sci
Ushtanit A, Peretokina I, Krylova L, Safonova S, Filippov A, Zimenkov D.   +5 more
europepmc   +1 more source

Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment. [PDF]

Nat Commun
Nyang'wa BT, Motta I, Moodliar R, Solodovnikova V, Rajaram S, Rasool M, Berry C, Moore DAJ, Davies G, Kloprogge F.   +9 more
europepmc   +1 more source

Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing. [PDF]

Nat Commun
Vambe D, Kay A, Ziyane M, Thunzini M, Thi SS, de Araujo L, Dreyer V, Niemann T, Sibandze B, Masina S, Cabibbe AM, Furin J, Mazuruse T, Dlamini L, Jele T, Mamba B, Maphalala G, Dlamini M, Dube M, Lukhele N, Cirillo DM, Mandalakas A, Lange C, Ngwenya S, Utpatel C, Dlamini S, Niemann S.   +26 more
europepmc   +1 more source

Breaking barriers in extensively drug-resistant TB: pretomanid-centred long regimen achieves cure in a bedaquiline-resistant strain. [PDF]

IJTLD Open
Schiuma M, Piubello A, Saluzzo F, Cattaneo D, Salari F, Covizzi A, Rizzo A, Fama F, Ciubotariu C, Lombardi A, Antinori S, Riva A, Cirillo DM, Gori A, Torre A.   +14 more
europepmc   +1 more source

The new era of tuberculosis treatment: Can novel drugs turn the tide? [PDF]

J Public Health Res
Pawar VD, Patil R.
europepmc   +1 more source

Outcomes in patients with multidrug- or rifampin-resistant tuberculosis treated with bedaquiline and/or delamanid under the South Korean nationwide approval process. [PDF]

BMC Infect Dis
Hwang H, Shin JE, Seo S, Hong SJ, Jang MR, Kang H, Mok J, Kwon YS, Jeon D, Shim TS, Yim JJ.   +10 more
europepmc   +1 more source

Cost-effectiveness evaluation of bedaquiline- and delamanid-containing regimens for multidrug-/rifampicin-resistant tuberculosis in China: a retrospective study based on three nationwide, real-world multicenter cohorts. [PDF]

J Thorac Dis
Sun D, Li Z, Qiu Y, Shu W, Zhang L, Gao J, Liu Y.   +6 more
europepmc   +1 more source

What is new in tuberculosis? [PDF]

Clin Med (Lond)
Myat Y, Cerrone M, Kon OM.
europepmc   +1 more source

Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model. [PDF]

Antimicrob Agents Chemother
Cummings JE, Woolhiser LK, Guglielmi V, Romano A, Pauly S, Zimmerman M, Kaya F, Walter ND, Robertson GT, Slayden RA.   +9 more
europepmc   +1 more source